Tempus AI and CRISPR Therapeutics: The Twin Engines of Precision Medicine
-
最新报道：Pfizer secured a three-year import tariff exemption in exchange for domestic drug price cuts, boosting healthcare stocks as the iShares Global Healthcare ETF (IXJ) rose ~7% since late September. Tempus AI (TEM) surged 201% YTD, with Q2 revenue up 90% to $314.6 million and gross margin expanding to 62%, driven by AI-powered genomic testing and data licensing. CRISPR Therapeutics (CRSP) gained 83.4% YTD, leveraging CRISPR-Cas9 gene editing with one approved therapy (CASGEVY) and 15 clinical programs, though it reported a Q2 net loss of $208.6 million.
下一篇
'Huge': Adam Back Reacts to First EU Country Buying Bitcoin
- Luxembourg's sovereign wealth fund (FSIL) has become the first in the eurozone to allocate...
24小时热点
热点专题
413027